On May 22, 2026, the Ministry of Health in Beira, Mozambique, will begin the roll-out of cabotegravir (CAB-LA), a long-acting injectable HIV prevention method. This follows a successful implementation study by Doctors Without Borders (MSF) that targeted high-risk populations, including men who have sex with men, sex workers, and transgender individuals. CAB-LA, administered every two months, offers a discreet alternative to daily oral PrEP pills, which can be challenging for many due to stigma or mobility issues. Dr. Antonio Flores, a senior HIV advisor at MSF, highlighted that preliminary findings show individuals on CAB-LA are more likely to adhere to the treatment compared to those using oral PrEP. MSF has donated 675 doses of CAB-LA to the Ministry of Health, which will now oversee its distribution in Beira. This transition not only ensures continued access to this essential preventive tool but also supports the development of a diverse HIV prevention strategy in Mozambique. With limited availability of other long-acting injectables like lenacapavir, CAB-LA remains a vital option for those at risk of HIV.